vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $15.2M, roughly 1.4× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -84.4%, a 90.9% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -65.2%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
JYNT vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $20.6M |
| Net Profit | $991.1K | $-17.3M |
| Gross Margin | 81.4% | — |
| Operating Margin | 4.9% | -106.0% |
| Net Margin | 6.5% | -84.4% |
| Revenue YoY | 3.1% | -65.2% |
| Net Profit YoY | 5510.5% | -173.8% |
| EPS (diluted) | $0.06 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | — | ||
| Q3 25 | $13.4M | — | ||
| Q2 25 | $13.3M | — | ||
| Q1 25 | $13.1M | $20.6M | ||
| Q4 24 | $14.7M | $37.4M | ||
| Q3 24 | $30.2M | $19.6M | ||
| Q2 24 | $30.3M | $94.7M | ||
| Q1 24 | $29.7M | $59.1M |
| Q4 25 | $991.1K | — | ||
| Q3 25 | $855.0K | — | ||
| Q2 25 | $93.4K | — | ||
| Q1 25 | $967.8K | $-17.3M | ||
| Q4 24 | $17.7K | $1.1M | ||
| Q3 24 | $-3.2M | $-14.0M | ||
| Q2 24 | $-3.6M | $55.0M | ||
| Q1 24 | $947.0K | $23.5M |
| Q4 25 | 81.4% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 79.1% | — | ||
| Q1 25 | 77.3% | — | ||
| Q4 24 | 78.4% | — | ||
| Q3 24 | 90.7% | — | ||
| Q2 24 | 90.7% | — | ||
| Q1 24 | 90.9% | — |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | -8.6% | — | ||
| Q1 25 | -5.2% | -106.0% | ||
| Q4 24 | 5.5% | -15.7% | ||
| Q3 24 | -1.6% | -110.7% | ||
| Q2 24 | -5.9% | 56.4% | ||
| Q1 24 | -1.4% | 35.7% |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 7.4% | -84.4% | ||
| Q4 24 | 0.1% | 3.0% | ||
| Q3 24 | -10.5% | -71.7% | ||
| Q2 24 | -11.9% | 58.1% | ||
| Q1 24 | 3.2% | 39.7% |
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | $0.06 | $-0.42 | ||
| Q4 24 | $0.01 | $-0.20 | ||
| Q3 24 | $-0.21 | $-0.35 | ||
| Q2 24 | $-0.24 | $1.55 | ||
| Q1 24 | $0.06 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.1M | $417.3M |
| Total Assets | $61.0M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | — | ||
| Q3 25 | $29.7M | — | ||
| Q2 25 | $29.8M | — | ||
| Q1 25 | $21.9M | $67.8M | ||
| Q4 24 | $25.1M | $101.2M | ||
| Q3 24 | $20.7M | $78.0M | ||
| Q2 24 | $17.5M | $185.3M | ||
| Q1 24 | $18.7M | $68.4M |
| Q4 25 | $15.1M | — | ||
| Q3 25 | $22.7M | — | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $22.8M | $417.3M | ||
| Q4 24 | $20.7M | $428.7M | ||
| Q3 24 | $20.5M | $422.4M | ||
| Q2 24 | $23.2M | $429.9M | ||
| Q1 24 | $26.2M | $269.4M |
| Q4 25 | $61.0M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $73.2M | — | ||
| Q1 25 | $80.1M | $486.5M | ||
| Q4 24 | $83.2M | $526.3M | ||
| Q3 24 | $79.6M | $554.6M | ||
| Q2 24 | $82.4M | $582.0M | ||
| Q1 24 | $85.7M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-38.5M |
| Free Cash FlowOCF − Capex | $334.7K | $-39.7M |
| FCF MarginFCF / Revenue | 2.2% | -192.9% |
| Capex IntensityCapex / Revenue | 9.9% | 5.6% |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $868.6K | — | ||
| Q1 25 | $-3.7M | $-38.5M | ||
| Q4 24 | $9.4M | $-31.6M | ||
| Q3 24 | $3.4M | $-24.3M | ||
| Q2 24 | $-973.5K | $39.8M | ||
| Q1 24 | $2.8M | $-25.5M |
| Q4 25 | $334.7K | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $363.6K | — | ||
| Q1 25 | $-4.0M | $-39.7M | ||
| Q4 24 | $8.2M | $-32.2M | ||
| Q3 24 | $3.2M | $-24.9M | ||
| Q2 24 | $-1.2M | $38.8M | ||
| Q1 24 | $2.4M | $-26.4M |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | -30.8% | -192.9% | ||
| Q4 24 | 55.9% | -86.2% | ||
| Q3 24 | 10.6% | -127.3% | ||
| Q2 24 | -4.1% | 41.0% | ||
| Q1 24 | 8.1% | -44.6% |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 2.5% | 5.6% | ||
| Q4 24 | 8.1% | 1.7% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.9% | 1.1% | ||
| Q1 24 | 1.3% | 1.4% |
| Q4 25 | 1.86× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | 2.97× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
TRDA
Segment breakdown not available.
